Table 2.

Designs of the identified studies evaluating restriction policies for pregabalin

	Margolis et al., 2009 [27]	Margolis, et al., 2010 [28]	Bazalo et al., 2010 [26]	Udall et al., 2014 [30]	Suehs et al., 2014 [31]	Placzek et al., 2014 [29]	Null et al., 2016 [32]	Martin et al., 2016 [33]
Study design (population)	Retrospective database (Medicaid)	Retrospective database (commercial)	Modeling (IMS prescription data)	Retrospective database (commercial)	Retrospective database (Medicare)	Retrospective database (commercial)	Retrospective database (Medicare & commercial)	Retrospective database (commercial)
Number of patients	Restricted, n = 424; unrestricted, n = 5153	Restricted, n = 2084; unrestricted, n = 1320	Not applicable	Restricted, n = 3876; unrestricted, n = 3876	Restricted, n = 13,911; unrestricted, n = 13,911	Restricted, n = 29,283; unrestricted, n = 463	Not applicable	Restricted, n = 1218; unrestricted, n = 1218
Restriction type	PA	PA	PA	ST	ST	PA	ST	Mail order requirement
Conditions evaluated	PHN; pDPN	PHN; pDPN	PHN; pDPN; FM; partial-onset seizures	PHN; pDPN; FM	PHN; pDPN	pDPN; FM	pDPN; FM; PHN	PHN; pDPN; FM; partial-onset seizures

Abbreviations: FM fibromyalgia, PA prior authorization, pDPN painful diabetic peripheral neuropathy, PHN postherpetic neuralgia, ST step therapy